*ST美谷(000615) - 2021 Q4 - 年度财报

Business Transition - The company reported a significant change in its main business, shifting from real estate to focus on chemical fiber new materials and medical beauty services[18]. - The company has undergone a major asset sale related to its real estate business, with the relevant companies completing industrial and commercial change registration[4]. - The company has completed the divestiture of its real estate business, focusing on medical beauty and chemical fiber new materials, with the medical beauty sector contributing to steady revenue growth post-pandemic[35]. - The company has shifted its main business focus to viscose new materials and medical beauty services after divesting from real estate operations[65]. - The company has divested its real estate business to concentrate on the medical beauty sector, optimizing its asset structure and business focus[53]. Financial Performance - The company's operating revenue for 2021 was approximately ¥1.54 billion, a decrease of 22.58% compared to ¥1.99 billion in 2020[19]. - The net profit attributable to shareholders was a loss of approximately ¥253.37 million, representing an 88.03% increase in losses compared to a loss of ¥134.75 million in 2020[19]. - The net profit after deducting non-recurring gains and losses was a loss of approximately ¥671.50 million, which is a 234.01% increase in losses compared to a loss of ¥201.04 million in 2020[19]. - The total assets at the end of 2021 were approximately ¥4.32 billion, a decrease of 54.29% from ¥9.45 billion at the end of 2020[19]. - The net assets attributable to shareholders decreased by 14.48%, totaling approximately ¥1.47 billion at the end of 2021 compared to ¥1.71 billion at the end of 2020[19]. Audit and Compliance - The company’s financial report has been audited by Zhongzheng Huayuan Accounting Firm, which issued an unqualified opinion with emphasis on certain matters[4]. - The company faced uncertainty regarding its ability to continue as a going concern, as indicated in the audit report for the most recent year[19]. - The company has not yet received approval from the China Securities Regulatory Commission regarding its industry classification results for Q4 2021[5]. - The company has not engaged in any securities or derivative investments during the reporting period[86][87]. - The company did not have any fundraising activities during the reporting period[88]. Strategic Development - The company plans to expand its medical beauty services and products through mergers and acquisitions, focusing on the Yangtze River Delta and Guangdong-Hong Kong-Macau Greater Bay Area[46]. - The company aims to establish a national beauty health brand and become a leading integrator in the beauty and health industry[46]. - The company is exploring market expansion opportunities and potential mergers and acquisitions to enhance its competitive position[108]. - The company aims to improve operational efficiency by implementing new technologies, expecting a reduction in operational costs by 10% in 2022[125]. - The company is committed to enhancing management efficiency and effectiveness through a global partner program and by attracting strategic talent in the medical beauty sector[101]. Research and Development - The company has completed the research and development of 60D ultra-fine filament, which meets the GB/T 13758 standard and is expected to increase profit by approximately 30,000 yuan per ton compared to regular filament[69]. - The company is actively pursuing new product development and market expansion, including collaborations with universities and research institutions[71]. - The company’s R&D investment amounted to ¥26,310,327.93, representing a 39.03% increase compared to ¥18,924,275.97 in the previous year[72]. - The company has established a salary distribution system linked to employee positions, performance, and capabilities, ensuring timely salary payments[145]. - The company is focused on becoming a leading supplier of medical mask substrates, targeting new materials for drug-loaded masks and enhancing production capacity for green fiber products[100]. Governance and Shareholder Relations - The company held 6 shareholder meetings during the reporting period, ensuring equal voting rights for all shareholders, particularly minority investors[111]. - The board of directors consists of 9 members, including 3 independent directors, and held 14 meetings throughout the year, adhering to legal and regulatory requirements[112]. - The company emphasizes the importance of stakeholder rights, aiming for a balance of interests among shareholders, employees, and suppliers[113]. - The company has established an independent accounting system and financial management practices, ensuring separate financial operations from the controlling shareholder[116]. - The company is committed to improving information disclosure quality and compliance with relevant laws and regulations[169]. Environmental Responsibility - The company operates three wastewater treatment plants with a total daily processing capacity of 54,500 tons, achieving a COD removal rate of 96.35%[174]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[176]. - The company emphasizes employee rights protection, adhering to labor laws and providing comprehensive training and social insurance, including medical and pension benefits[177]. - The company has invested nearly 100 million yuan in social welfare initiatives, including building five hope primary schools in impoverished areas[178]. - The company maintains a high level of resource utilization and strictly controls pollutant emissions during production, promoting green office practices[179]. Market Position and Future Outlook - The medical beauty market in China is characterized by a large consumer base, high growth potential, and low penetration, indicating significant room for expansion in the coming years[32]. - The company’s medical beauty materials have received international certifications, reinforcing its commitment to quality and sustainability in the production of high-end medical beauty products[36]. - The company is committed to building a nationwide trusted medical beauty brand and becoming an integrated player in the medical beauty ecosystem[97]. - The company plans to conduct a special audit report to verify the cumulative net profit of the target company at the end of the performance commitment period[191]. - The company is expected to receive cash compensation if the target company's cumulative net profit does not meet the commitment by the end of the performance period[191].